Vicore Pharma: Buloxibutid granted Fast Track Designation in IPF
Vicore Pharma's buloxibutid in IPF, currently evaluated in a phase 2b trial, was granted Fast Track Designation by the FDA, which offers some important advantages and can be leveraged for i) more frequent interactions with the FDA, ii) the possibility to be eligible for accelerated approval one theVicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.